1Westman KW,Selga D, Bygren P, et al. Clinical evaluation of acapture EL1SA for detection of proteinase-3 antineutrophil cytolfiasmic antibody. Kidney lnt, 1998,53:1230-1236.
2Rao JY, Wernberg M, Oddone EZ, et al. The role of antineutrophil cytoplasmicantbody (c-ANCA) testing in the diagnosis of Wegener's granulomatosis. Ann Intern Med, 1995,123:425-432.
3Hagen EC, Daha MR, Hermaus J,et al. Diagnostic value of standardized assays for ariti-neutrophil cytophasmic antibodies in idiopathic systemic vaseuiifis EC/BCR project for ANCA assay standardization. Kidney. Int, 1998,53 : 743-753.
4Vassilopoulos D; Niles JL, Vilia-Forte A, et al. Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction. Arthritis Rheum (Arthritis care research) ,2003,49:151-155.
5Komocsi A, Reuter M, Heller M, et al. Active disease and residual damage in treated Wegener's granulomatosis: an observational study using pulmonary high-resolution computed tomography. Eur Radiol, 2003,13: 3642.
6Aasarod K, lversen BM, Hammerstrom J, et al. Wegener' s granulornatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant, 2000,15 : 611-618.
7Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol, 2003,30: 80-88.
8Guillevin L, Cordior JF, Lhote F, et al. Aprospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener' s granulomatosis. Arthritis Rheum, 1997, 409: 2187-2198.
9Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q J Med, 1997,40:218-2198.
10de Groot K,Adu D,Savag CO,et al.The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrel Dial Transplant, 2001,16: 2018-2027.
